Javier Loscertales
About
In The Last Decade
Javier Loscertales
40 papers receiving 255 citations
Peers
Comparison fields: 5 of 35
- Genetics 226
- Pathology and Forensic Medicine 202
- Immunology 77
- Hematology 67
- Oncology 37
Countries citing papers authored by Javier Loscertales
This map shows the geographic impact of Javier Loscertales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Loscertales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Loscertales more than expected).
Fields of papers citing papers by Javier Loscertales
This network shows the impact of papers produced by Javier Loscertales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Loscertales. The network helps show where Javier Loscertales may publish in the future.
Co-authorship network of co-authors of Javier Loscertales
This figure shows the co-authorship network connecting the top 25 collaborators of Javier Loscertales. A scholar is included among the top collaborators of Javier Loscertales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Loscertales. Javier Loscertales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 6 | |
| 3 | 3 | |
| 4 | 1 | |
| 5 | 9 | |
| 6 | 10 | |
| 7 | 3 | |
| 8 | 1 | |
| 9 | IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY | 4 |
| 10 | 13 | |
| 11 | 8 | |
| 12 | 1 | |
| 13 | 1 | |
| 14 | 2 | |
| 15 | Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2 | 3 |
| 16 | 1 | |
| 17 | 10 | |
| 18 | Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study | 1 |
| 19 | 3 | |
| 20 | Deutsche Investitionen in Spanien 1870-1920 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.